[Criteria for the evaluation of myocardial contractility of the hypertrophied and insufficient heart. II].
D000200:Action Potentials; D000818:Animals; D001022:Aortic Valve Insufficiency / Q000503:physiopathology*; D001794:Blood Pressure; D006328:Cardiac Catheterization; D002301:Cardiac Glycosides / Q000494:pharmacology; D002306:Cardiac Volume; D002415:Cats; D005934:Glucagon / Q000502:physiology; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D006329:Heart Conduction System / Q000503:physiopathology; D006333:Heart Failure / Q000503:physiopathology*; D006334:Heart Function Tests; D006352:Heart Ventricles; D006439:Hemodynamics; D008012:Lidocaine / Q000494:pharmacology; D008944:Mitral Valve Insufficiency / Q000503:physiopathology; D009119:Muscle Contraction; D010101:Oxygen Consumption; D010210:Papillary Muscles / Q000503:physiopathology; D011433:Propranolol / Q000494:pharmacology; D011665:Pulmonary Valve Insufficiency / Q000503:physiopathology; D011817:Rabbits
D002301:Cardiac Glycosides; D005934:Glucagon; D008012:Lidocaine; D011433:Propranolol
Kriterien zur beurteilung der Myokardcontractilität am hypertrophierten und insuffizienten Herzen. I.